• Belite Bio to deliver oral presentation at Retina China 2026 in Nanjing, China, May 21-23, 2026.
• Phase 3 DRAGON topline data on tinlarebant in Stargardt disease type 1 to be presented May 22, 2026, 1:54-2:02 p.m. CST.
• Company highlighted previously disclosed result showing 35.7% reduction in growth rate of atrophic retinal lesions versus placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150800PRIMZONEFULLFEED9721089) on May 15, 2026, and is solely responsible for the information contained therein.